Scientists identify protein that drives survival of gastrointestinal tumors

Since the introduction of Gleevec as a treatment for gastrointestinal stromal tumors, survival rates have climbed dramatically and recurrence has fallen by two-thirds. But over time, many patients develop resistance to the drug. Now, scientists at Rockefeller University and Memorial Sloan-Kettering Cancer Center have identified a molecule that acts as a survival factor for gastrointestinal tumors, a finding that may lead to next-generation therapies that can pick up where Gleevec leaves off.

Read the whole article on The Rockefeller University

More from The Rockefeller University